HR and breast cancer: The use of the Oncotype DX® test for therapeutic decision-making in patients with HR+, HER2−, early BC proved to be dominant (i.e., associated with improved clinical outcomes and lower costs) compared with SoC involving therapeutic decisions being made solely based on clinicopathological characteristics.